Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Pharmacogenomic decision support for modulators of the nmda, glycine, and ampa receptors

A technology of regulators and drugs, applied in the fields of genomics, drugs or prescriptions, proteomics, etc.

Pending Publication Date: 2021-11-09
RGT UNIV OF MICHIGAN
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thus, rTMS and ketamine exhibit similar mechanisms of action to alleviate TRD, but about half of all TRD patients do not respond to treatment with either treatment option

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmacogenomic decision support for modulators of the nmda, glycine, and ampa receptors
  • Pharmacogenomic decision support for modulators of the nmda, glycine, and ampa receptors
  • Pharmacogenomic decision support for modulators of the nmda, glycine, and ampa receptors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0054] While the following text sets forth a detailed description of many different embodiments, it should be understood that the legal scope of this description is defined by the words of the claims set forth at the conclusion of this disclosure. The detailed description should be construed as exemplary only and does not describe every possible embodiment since describing every possible embodiment would be impractical, if not impossible. There are many alternative embodiments, which could be implemented, using either current technology or technology developed after the filing date of this patent, which would still fall within the scope of the claims.

[0055] It should also be understood that there is no intention to limit the meaning of said term unless the term is expressly defined in this patent using the sentence "As used herein, the term '______' is defined herein to mean..." or a similar sentence, whether express or implied, beyond their plain or ordinary meaning, and t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Methods for identifying patients diagnosed with treatment resistant or refractory depression, pain or other clinical indications who are eligible to receive N-methyl-D-aspartate receptor antagonist, glycine receptor beta (GLRB) modulator, or alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)-based therapies to include determining the appropriate medication, an optimal dose for each patient, and determining which patients are not eligible to receive the therapy. The pharmacogenomic clinical decision support assays include targeted single nucleotide polymorphisms and clinical values or a combination of targeted single nucleotide polymorphisms, targeted ketamine- specific expansion and contraction of topologically associated domains, and clinical values. The methods described herein allow for a more effective determination of which patients will experience drug efficacy and which patients will experience adverse drug events. The methods provide personalized patient recommendations for dose, the frequency of medication administration, and recommendations on drug choice.

Description

[0001] References to related applications [0002] This application requires an application titled "Methods and Systems to Reconstruct DrugSpatial Networks from Pharmacogenomic Regulatory Interactions and Uses Thereof" submitted on January 23, 2019 (1) U.S. Provisional Application Serial No. 62 / 795,705 and entitled "Companion Diagnostic Assays for N-Methyl-D-Aspartate Receptor Modulators" filed on January 23, 2019 methyl-D-Aspartate Receptor Modulators)" (2) U.S. Provisional Application Serial No. 62 / 795,710, the entire disclosure of each of which is hereby expressly incorporated by reference This article. technical field [0003] The technique described here is related to pharmacogenomic clinical decision support assays and can be used to select N-methyl-D-aspartate (NMDA) receptors, glycine receptors, and α-amino-3-hydroxy-5- Therapy of methyl-4-isoxazolepropionic acid (AMPA) receptors for depression (especially treatment-resistant or treatment-resistant depression) and o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G16H20/10
CPCG16H20/10G16B5/00G16B40/00G16B45/00G16B50/10G16B30/00G16H50/20G16H50/50
Inventor B·D·阿西G·A·希金斯A·艾德A·卡利宁N·里马鲁恩J·S·伯恩斯
Owner RGT UNIV OF MICHIGAN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com